文献速递免疫规划传染病防控与疫情报告

高剂量与标准剂量四价灭活流感疫苗在HIV感染者中的免疫原性与安全性:随机对照试验

Immunogenicity and safety of high-dose versus standard-dose quadrivalent inactivated influenza vaccine in patients living with HIV: a randomized controlled trial.
PubMed 文献 · Vaccine · 2026-09-17

该随机单盲对照试验比较了高剂量(60μg)与标准剂量(15μg)四价灭活流感疫苗在HIV感染者中的免疫原性和安全性。共110人入组,103人纳入符合方案分析。高剂量组对所有疫苗株的总体血清保护率显著高于标准剂量组(61.5% vs 39.2%,p=0.02),A/H3N2株血清保护率也显著更高(76.9% vs 52.9%,p=0.01)。两组不良事件发生率无显著差异,无严重疫苗相关事件。

要点

  • 高剂量IIV4可提高HIV感染者对所有疫苗株的总体血清保护率。
  • 高剂量IIV4对A/H3N2株的血清保护率显著优于标准剂量。
  • 高剂量与标准剂量IIV4的不良事件发生率无显著差异。

核心结论

  • 高剂量IIV4较标准剂量IIV4增强了对疫苗A/H3N2株的免疫原性,且未增加不良事件风险。

研究设计与样本

  • 随机、单盲、对照试验,比较高剂量IIV4(60μg,Efluelda,Sanofi)与标准剂量IIV4(15μg,Vaxigrip Tetra,Sanofi)。

主要发现

  • 总体血清保护率(所有四株)高剂量组为61.5%,标准剂量组为39.2%(p=0.02)。
  • A/H3N2株血清保护率高剂量组为76.9%,标准剂量组为52.9%(p=0.01)。
  • 多因素logistic回归显示高剂量IIV4(OR 2.7,95%CI 1.9-6.1,p=0.02)和女性(OR 2.5,95%CI 1.1-5.9,p=0.04)与所有株血清保护独立相关。
  • 不良事件发生率:高剂量组55.8%,标准剂量组58.8%(p=0.75),最常见为局部反应,无严重疫苗相关事件。

关键数值与推荐

  • 血清保护定义为接种后一个月血凝抑制抗体滴度≥1:40。
  • 高剂量IIV4为60μg,标准剂量IIV4为15μg。

临床怎么用

  • 对于HIV感染者,高剂量IIV4可能作为提高流感疫苗免疫原性的选择,尤其针对A/H3N2株。
  • 高剂量IIV4未增加不良事件风险,安全性可接受。

局限性

  • 研究未评估临床有效性,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Influenza remains a major cause of morbidity in people living with HIV (PLWH), and despite recommendations for annual vaccination with the standard-dose (SD) quadrivalent inactivated influenza vaccine (IIV4), immune responses are often suboptimal in this population. To address this gap, we conducted a randomized, single-blinded, controlled trial to compare the immunogenicity and safety of the high-dose (HD) IIV4 (60 μg, Efluelda, Sanofi) with the SD IIV4 (15 μg, Vaxigrip Tetra, Sanofi). Vaccinations were administered between August and December 2023, and seroprotection (SP) was defined as a hemagglutination-inhibition antibody titer ≥1:40 at one month post-vaccination. Adverse events (AEs) were actively monitored. Of 110 participants enrolled, 103 were included in the per-protocol analysis (52 HD; 51 SD). The mean age was 49.6 years, 63.1% were male, and the median CD4 count was 555 cells/mm3. Most participants were virologically suppressed (93.2%), and more than half were receiving integrase inhibitor-based antiretroviral regimens (57.3%). Overall, 50.5% of participants achieved SP to all four vaccine strains. The HD group demonstrated significantly higher overall SP compared with the SD group (61.5% vs. 39.2%, p = 0.02). In strain-specific analyses, a significantly higher seroprotection rate was observed for A/H3N2 (76.9% vs. 52.9%, p = 0.01). In multivariable logistic regression, receipt of HD IIV4 (OR 2.7, 95% CI 1.9-6.1, p = 0.02) and female sex (OR 2.5, 95% CI 1.1-5.9, p = 0.04) were independently associated with SP against all strains. AEs were reported in 55.8% of HD and 58.8% of SD recipients (p = 0.75), most commonly local reactions, with no severe vaccine-related events observed. In conclusion, HD IIV4 enhanced immunogenicity against the vaccine A/H3N2 strain compared with SD IIV4, without increasing the risk of adverse events compared to SD IIV4. These findings suggest that HD IIV4 may enhance immunogenicity in PLWH and warrant further investigation in studies evaluating clinical effectiveness (TCTR20230501002).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Laoharattanahirun N, Kiertiburanakul S, Boonnak K, et al. Immunogenicity and safety of high-dose versus standard-dose quadrivalent inactivated influenza vaccine in patients living with HIV: a randomized controlled trial. Vaccine. 2026. PMID: 42753388. doi:10.1016/j.vaccine.2026.129166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。